[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"focus\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:focus":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":4},"100648412","a-clinical-trial-to-evaluate-the-effects-of-the-edgeease-pmam-system-on-mood-mental-clarity-sleep-quality-and-digestive-wellbeing-100648412",false,"NCT07721506","A Clinical Trial to Evaluate the Effects of the Edge+Ease PM+AM System on Mood, Mental Clarity, Sleep Quality, and Digestive Wellbeing","Inclusion Criteria:\n\n* Male and female adults aged 18 to 65 years.\n* Self-reports difficulty falling asleep, staying asleep, or having poor sleep quality overall, in the last 4 weeks.\n* Self-reports seeking support in at least one of the following domains: Difficulty switching off, perceived stress load, mental overload, next-day mental fatigue, reduced mental clarity or reduced cognitive readiness.\n* Generally healthy.\n* Willing and able to take the PM product (one serving mixed in water) in the evening and the AM product (two capsules with food) in the morning daily for 12 weeks.\n* Willing to maintain current diet, exercise, caffeine, alcohol, and sleep routines for the duration of the study.\n* Willing to wear a Fitbit continuously during the trial, and for 7 days prior to starting the test product.\n* Resides in the United States.\n\nExclusion Criteria:\n\n* Known allergy or hypersensitivity to any ingredient in the test product.\n* Currently pregnant, breastfeeding, or trying to conceive, or will be during the study period.\n* Currently undergoing treatment for cancer, or have had a serious illness requiring hospitalization in the last 3 months.\n* Diagnosed severe psychiatric disorder (e.g., bipolar disorder, schizophrenia, major depressive disorder requiring active treatment adjustment) that, in the judgment of the Investigator, would compromise participation or interpretation of results.\n* Diagnosed inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis), celiac disease, or other significant gastrointestinal condition requiring active management.\n* Current use of prescription antidepressants\u002Fanxiolytics, or other prescription neurologically-active medications that have been initiated or had a dose change within the past 90 days.\n* Current use of prescription sleep medications.\n* Regular use (i.e. more than once per week) of melatonin, sedating antihistamines, CBD\u002FTHC used for sleep, valerian, ashwagandha, or other sleep-targeted supplements.\n* Initiation of a new dietary supplement targeted at sleep, mood, cognition, or digestion within the 30 days prior to enrollment, or planning to start such a supplement during the study.\n* Heavy drinkers, defined as more than 8 alcoholic drinks per week for women and more than 15 alcoholic drinks per week for men.\n* Currently taking thyroid medication.\n* Currently testing, or plan to in the next 12 weeks, a product for another research study.",true,"ALL","18 Years","65 Years",{"count":20,"type":21},35,"ESTIMATED","INTERVENTIONAL",[24],"NA","This is a decentralized, single-arm, open-label clinical trial evaluating the effects of the Edge+Ease PM+AM dietary supplement system on sleep quality, mood, mental clarity, focus, and digestive comfort in 35 generally healthy adults aged 18-65 years over 12 weeks of daily use.\n\nParticipants will take the Edge+Ease PM product (one serving of powder mixed in approximately 150-250 mL water) in the evening approximately 60-90 minutes before bedtime, and the Edge+Ease AM product (two capsules) in the morning with food. All study activities are conducted remotely via the Citruslabs platform. Participants will complete questionnaires at Baseline, Week 4, Week 8, and Week 12, and will wear a Fitbit continuously beginning 7 days before product use through the end of the 12-week intervention period to provide objective sleep data.",[27,28,29,30,31,32,33],"Sleep Quality","Mood","Mental Clarity","Brain Fog","Digestive Comfort","Focus","Evening Wind-Down","NOT_YET_RECRUITING","2026-07-18",{"date":37,"type":38},"2026-07-23","ACTUAL",{"date":40,"type":21},"2026-08",{"date":42,"type":21},"2026-12",{"name":44,"class":45},"Edge+Ease","INDUSTRY",{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":15,"sex":16,"minAge":53,"maxAge":18,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":57,"conditions":58,"keywords":62,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":82},"100580434","a-clinical-trial-to-assess-cognitive-effects-of-cognitive-nutritional-supplement-in-general-population-100580434","NCT06837246","A Clinical Trial to Assess Cognitive Effects of Cognitive Nutritional Supplement in General Population","A Randomized, Parallel, Double-Blind, Placebo-Controlled Study to Assess Cognitive Effects of Cognitive Nutritional Supplementation in the General Population","Inclusion Criteria:\n\n1. Male or female, ≥25 to ≤65 years of age at screening.\n2. English is the primary spoken language.\n3. Able to operate a study-provided iPad connected to the internet with a strong and reliable internet connection.\n4. Willing to consume 3 capsules per day for 12 weeks.\n5. Willing to review and follow all training materials provided.\n6. Willing to avoid alcohol, marijuana\u002Fhemp products (including CBD products), and vigorous physical activity 24 h prior to the baseline (week 0), mid-point (Week 6), and end of study (Week 12) cognition testing days.\n7. Non-user or former user (cessation ≥12 months of screening) of tobacco or nicotine products (e.g., cigarette smoking, vaping, chewing tobacco, nicotine gums or lozenges) with no plans to begin use during the study period.\n8. Willing to maintain habitual diet and physical activity patterns throughout the study.\n9. Willing to refrain from exclusionary medications, supplements, and products throughout the study.\n10. Understands the study procedures and signs forms providing informed consent to participate in the study and authorizes the release of relevant protected health information to the Principal Investigator.\n\nExclusion Criteria:\n\nCognition related criteria\n\n1. Diagnosed neurological disorder such as Alzheimer's disease, Parkinson's disease, stroke, intracranial hemorrhage, or any brain lesions including tumors.\n2. Diagnosed mental health disorder, such as major depressive disorder or any anxiety disorder. The use of daily or as-needed prescription medications to treat these conditions is also exclusionary.\n3. Any infective or inflammatory brain disease, including those of viral, fungal, or syphilitic etiologies.\n4. Elective hospitalizations planned (e.g., elective cosmetic procedures) during the study period.\n5. Color blindness or visual impairments that cannot be corrected with glasses or contact lenses.\n6. Diagnosed sleep disorder (e.g., sleep apnea) or occupation where sleep during the overnight hours is irregular (e.g., 3rd shift of overnight workers).\n7. History of repeated head injury (e.g., concussions from sports activities) or single trauma resulting in a period of unconsciousness lasting 1 h or more.\n8. Diagnosis of a learning and\u002For behavioral disorders such as dyslexia.\n9. Diagnosis of attention-deficit\u002Fhyperactivity disorder (ADHD).\n10. Use of any dietary supplements, other than a conventional once-daily multivitamin\u002Fmineral supplement that does not contain certain nutrient with cognitive effects, during the study period. Participants will be allowed to discontinue use of exclusionary dietary supplements during the screening period.\n11. Experienced a major life stress event, including the death of a loved one, marriage or divorce, birth of a child, unemployment, or moved to a new residence, within the last 6 months.\n\n    General health related criteria\n12. History or presence of cancer in the prior two years, except for non-melanoma skin cancer.\n13. Female who is pregnant, planning to be pregnant during the study period, lactating, or is of childbearing potential and unwilling to commit to the use of a medically approved form of contraception throughout the study period.\n\n    General safety related criteria\n14. Exposure to any non-registered drug product or has participated in another intervention study within 30 days prior to screening.\n15. Recent history (within 12 months of visit 1) of alcohol or substance abuse. Alcohol abuse is defined as \\>14 drinks per week (1 drink = 12 oz. beer, 5 oz. wine, or 1½ oz. distilled spirits).\n16. Another household member is a current participant in this study.\n17. Any condition the Investigator believes would interfere with his ability to provide informed consent, comply with the study protocol, or which might confound the interpretation of the study results or put the person at undue risk.\n\n6.2.1 Excluded Products\n\n* Tobacco \u002F nicotine products within 12 months of screening and throughout the study period\n* Any non-registered drug product within 30 days of screening\n* Alcohol within 24 h of each cognition test day\n* Marijuana\u002Fhemp products (including CBD products) within 24 h of each cognition test day\n* Current use of any medication used to treat mental health disorders, such as major depressive disorder or any anxiety disorder\n* Current use of any medications used to treat ADHD\n* Current use of any dietary supplements, other than a conventional once-daily multivitamin\u002Fmineral supplement that does not contain certain nutrient with cognitive effect. Participants will be allowed to discontinue use of exclusionary dietary supplements during the screening period.","25 Years",{"count":55,"type":21},422,[24],"This is a double-blind, randomized, 12-week parallel study that aims to determine the effects of a cognitive nutritional supplement for 12 weeks on cognition parameters specific to attention\u002Ffocus related domains, compared to a placebo control, in a general population of adult men and women in the United States.",[59,60,61,32],"Cognition","Concentration","Attention",[63,64,65,66,67,68,69,70,71],"cognition","concentration","attention","problem-solving","capsule","clinical trial","placebo-controlled","focus","memory","RECRUITING","2025-04-10",{"date":75,"type":38},"2025-04-15",{"date":77,"type":38},"2025-02-24",{"date":79,"type":21},"2025-09-30",{"name":81,"class":45},"Pharmavite LLC",1]